245 related articles for article (PubMed ID: 23881924)
21. Conventional chemotherapy and perspectives for molecular-based oncological treatment in pediatric hemispheric low-grade gliomas.
Fernández MB; Alonso VP
Childs Nerv Syst; 2016 Oct; 32(10):1939-45. PubMed ID: 27659836
[TBL] [Abstract][Full Text] [Related]
22. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
Plant-Fox AS; O'Halloran K; Goldman S
Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Dabrafenib in Pediatric Patients with
Hargrave DR; Bouffet E; Tabori U; Broniscer A; Cohen KJ; Hansford JR; Geoerger B; Hingorani P; Dunkel IJ; Russo MW; Tseng L; Dasgupta K; Gasal E; Whitlock JA; Kieran MW
Clin Cancer Res; 2019 Dec; 25(24):7303-7311. PubMed ID: 31811016
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Role of BRAF Mutation in Low-Grade Gliomas: Meta-analysis.
Kai Z; Dingyang L; Zhuanyi Y
World Neurosurg; 2021 Mar; 147():42-46. PubMed ID: 33316486
[TBL] [Abstract][Full Text] [Related]
25. T2-FLAIR Mismatch Sign in Pediatric Low-Grade Glioma.
Wagner MW; Nobre L; Namdar K; Khalvati F; Tabori U; Hawkins C; Ertl-Wagner BB
AJNR Am J Neuroradiol; 2023 Jul; 44(7):841-845. PubMed ID: 37348970
[TBL] [Abstract][Full Text] [Related]
26. MR Imaging of Pediatric Low-Grade Gliomas: Pretherapeutic Differentiation of
Trasolini A; Erker C; Cheng S; Crowell C; McFadden K; Moineddin R; Sargent MA; Mata-Mbemba D
AJNR Am J Neuroradiol; 2022 Aug; 43(8):1196-1201. PubMed ID: 35863783
[TBL] [Abstract][Full Text] [Related]
27. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Johnson BE; Mazor T; Hong C; Barnes M; Aihara K; McLean CY; Fouse SD; Yamamoto S; Ueda H; Tatsuno K; Asthana S; Jalbert LE; Nelson SJ; Bollen AW; Gustafson WC; Charron E; Weiss WA; Smirnov IV; Song JS; Olshen AB; Cha S; Zhao Y; Moore RA; Mungall AJ; Jones SJM; Hirst M; Marra MA; Saito N; Aburatani H; Mukasa A; Berger MS; Chang SM; Taylor BS; Costello JF
Science; 2014 Jan; 343(6167):189-193. PubMed ID: 24336570
[TBL] [Abstract][Full Text] [Related]
28. Benign Glioma.
Wu PB; Filley AC; Miller ML; Bruce JN
Adv Exp Med Biol; 2023; 1405():31-71. PubMed ID: 37452934
[TBL] [Abstract][Full Text] [Related]
29. [Low grade glioma with MYBL1 alteration: Case report of an uncommon pediatric neoplasm].
Appay R; Tauziède-Espariat A; Silva K; Fritih R; Scavarda D; Delteil C; Varlet P; Figarella-Branger D
Ann Pathol; 2021 Feb; 41(1):129-133. PubMed ID: 32732147
[TBL] [Abstract][Full Text] [Related]
30. Low-grade developmental and epilepsy associated brain tumors: a critical update 2020.
Slegers RJ; Blumcke I
Acta Neuropathol Commun; 2020 Mar; 8(1):27. PubMed ID: 32151273
[TBL] [Abstract][Full Text] [Related]
31. Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review.
Nobusawa S; Hirato J; Yokoo H
Brain Tumor Pathol; 2014 Oct; 31(4):229-33. PubMed ID: 25182241
[TBL] [Abstract][Full Text] [Related]
32. Molecular characteristics of pediatric high-grade gliomas.
Chamdine O; Gajjar A
CNS Oncol; 2014 Nov; 3(6):433-43. PubMed ID: 25438814
[TBL] [Abstract][Full Text] [Related]
33. A single-center study of the clinicopathologic correlates of gliomas with a MYB or MYBL1 alteration.
Chiang J; Harreld JH; Tinkle CL; Moreira DC; Li X; Acharya S; Qaddoumi I; Ellison DW
Acta Neuropathol; 2019 Dec; 138(6):1091-1092. PubMed ID: 31595312
[No Abstract] [Full Text] [Related]
34. Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.
Horbinski C; Nikiforova MN; Hagenkord JM; Hamilton RL; Pollack IF
Neuro Oncol; 2012 Jun; 14(6):777-89. PubMed ID: 22492957
[TBL] [Abstract][Full Text] [Related]
35. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
van Tilburg CM; Kilburn LB; Perreault S; Schmidt R; Azizi AA; Cruz-Martínez O; Zápotocký M; Scheinemann K; Meeteren AYNS; Sehested A; Opocher E; Driever PH; Avula S; Ziegler DS; Capper D; Koch A; Sahm F; Qiu J; Tsao LP; Blackman SC; Manley P; Milde T; Witt R; Jones DTW; Hargrave D; Witt O
BMC Cancer; 2024 Jan; 24(1):147. PubMed ID: 38291372
[TBL] [Abstract][Full Text] [Related]
36. BRAF-Targeted Therapy in the Treatment of
Johanns TM; Ansstas G; Dahiya S
J Natl Compr Canc Netw; 2018 Apr; 16(4):451-454. PubMed ID: 29632063
[No Abstract] [Full Text] [Related]
37. Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss.
Kim YH; Nonoguchi N; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Mariani L; Giangaspero F; Tanaka Y; Nakazato Y; Vital A; Mittelbronn M; Perry A; Ohgaki H
Brain Pathol; 2012 Nov; 22(6):834-40. PubMed ID: 22568401
[TBL] [Abstract][Full Text] [Related]
38. Treatment of Pediatric Low-Grade Gliomas.
Sait SF; Giantini-Larsen AM; Tringale KR; Souweidane MM; Karajannis MA
Curr Neurol Neurosci Rep; 2023 Apr; 23(4):185-199. PubMed ID: 36881254
[TBL] [Abstract][Full Text] [Related]
39. Bithalamic gliomas may be molecularly distinct from their unilateral high-grade counterparts.
Broniscer A; Hwang SN; Chamdine O; Lin T; Pounds S; Onar-Thomas A; Chi L; Shurtleff S; Allen S; Gajjar A; Northcott P; Orr BA
Brain Pathol; 2018 Jan; 28(1):112-120. PubMed ID: 28032389
[TBL] [Abstract][Full Text] [Related]
40. BRAF Inhibition in
Kaley T; Touat M; Subbiah V; Hollebecque A; Rodon J; Lockhart AC; Keedy V; Bielle F; Hofheinz RD; Joly F; Blay JY; Chau I; Puzanov I; Raje NS; Wolf J; DeAngelis LM; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM
J Clin Oncol; 2018 Dec; 36(35):3477-3484. PubMed ID: 30351999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]